Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Lawmakers revive stem cell issue

Any confirmation hearings for a new NIH director almost certainly would focus attention on the stem cell issue. Although congressional threats to prohibit NIH funding of research

Read the full 279 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE